Palomares, T <br/><br/>
The addition of interleukin-2 to cyclophosphamide therapy can facilitate tumor growth of B16 melanoma.  [electronic resource] 

 -  Cancer immunology, immunotherapy : CII  May 1995 
 - 292-8 p.  digital 
<br/><br/> Publication Type: Comparative Study; Journal Article; Research Support, Non-U.S. Gov't 
<br/><br/><label>ISSN: </label>0340-7004 
<br/><br/><label>Standard No.: </label>10.1007/BF01519628  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Animals<br/>Combined Modality Therapy--adverse effects<br/>Cyclophosphamide--administration & dosage<br/>Drug Interactions<br/>Female<br/>Immunocompetence<br/>Immunocompromised Host<br/>Immunologic Factors--administration & dosage<br/>Injections<br/>Interleukin-2--administration & dosage<br/>Liver Neoplasms--drug therapy<br/>Melanoma, Experimental--drug therapy<br/>Mice<br/>Mice, Inbred C57BL<br/>Neoplasm Proteins--metabolism<br/>Neoplasm Transplantation<br/>Receptors, Interleukin-2--drug effects<br/>Spleen<br/>Whole-Body Irradiation--adverse effects